Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 402 abstracts

no pagination
Barta SK. To be or not to be HIV+, that is no longer the question. Blood. 2015 Jul 09;126(2):124-6.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Oct 22;373(17):1627-39.
Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr;15(2):e155-8.
Chu J, Li JG, Giannopoulos PF, Blass BE, Childers W, Abou-Gharbia M, Pratico D. Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Abeta and tau neuropathology in the triple-transgenic mice. Mol Psychiatry. 2015 Nov;20(11):1329-38.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.   PMCID: PMC5531172
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54.   PMCID: PMC4898971
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biology & Therapy. 2015 May;16(5):743-9.   PMCID: 4623021
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams S. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015 Jul 02;3(11):1257-68.   PMCID: 4984269
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Ito T, Kutikov A. Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews Urology. 2015 Feb;12(2):69-70.
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol. 2015 May;33(13):1482-90.   PMCID: PMC4404425
Kniazeva E, Hardy AN, Boukaidi SA, Woodruff TK, Jeruss JS, Shea LD. Primordial Follicle Transplantation within Designer Biomaterial Grafts Produce Live Births in a Mouse Infertility Model. Sci Rep. 2015 Dec 03;5:17709.   PMCID: PMC4668556
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015 Jan;16(12):1710-9.   PMCID: PMC4847811
Marks EI, Brennan M, El-Deiry WS. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biology & Therapy. 2015 Aug;16(8):1136-9.   PMCID: 4622690
Meng MB, Zaorsky NG, Deng L, Wang HH, Chao J, Zhao LJ, Yuan ZY, Ping W. Pericytes: a double-edged sword in cancer therapy. Future Oncol. 2015 Jan;11(1):169-79.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. The New England journal of medicine. 2015 Mar 05;372(10):923-32.   PMCID: 4405231
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use Female drug therapy pathology Male Middle Aged genetics Antineoplastic Combined Chemotherapy Protocols administration & dosage therapy adverse effects Aged Adult mortality metabolism Antineoplastic Agents antagonists & inhibitors methods drug effects Doxorubicin Mice 80 and over Aged Pyrimidines Mutation Treatment Outcome Monoclonal Antibodies Angiogenesis Inhibitors Disease Progression Neoplasm Metastasis Renal Cell Carcinoma Tumor Cell Line Signal Transduction Neoadjuvant Therapy analogs & derivatives Carcinogenesis metastatic colorectal adenocarcinoma Sulfonamides Pregnancy prevention & control Benzimidazoles Organ Sparing Treatments Vincristine Local Neoplasm Recurrence Kidney Neoplasms Indoles Fluorouracil Nephrons Rituximab Chemoradiotherapy complications Cyclophosphamide immunology Survival Analysis Inbred C57BL Mice Neoplasms Colorectal Neoplasms Tumor Biomarkers Monoclonal Antibodies-Murine-Derived BRCA1 Genes diagnosis Nephrectomy Pyrroles blood Ovarian Neoplasms Prospective Studies etiology Drug Dose-Response Relationship biosynthesis Cisplatin Prednisone Primary Ovarian Insufficiency doxorubicin Disease-Free Survival early stage cyclophosphamide Neoplastic Stem Cells Liquid Chromatography Signal transducer and activator of transcription STAT Maximum Tolerated Dose neovascularization Ros Ca 19-9 Vascular endothelial growth factor receptor VEGFR Reactive Oxygen Species Toxicity Pregnancy Rate CA-19-9 Antigen Ovarian cancer Camptothecin Fear Vitamin D Deficiency piperlongumine surgery Veliparib Brain Phenylurea Compounds Ribonucleic acid RNA Renal cell carcinoma RCC Transitional Cell Carcinoma Leucovorin Molecular Models Hydroxamic Acids Breast Neoplasms anti-angiogenesis therapy Fallopian Tube Neoplasms Arachidonate 12-Lipoxygenase neoplasms transplantation Mitogen-activated protein kinase MAPK CTLA-4 Antigen Non-Small-Cell Lung Carcinoma capecitabine use consolidation Positron-Emission Tomography Hepatocyte growth factor HGF Proportional Hazards Models Taxoids Ubiquitin-Protein Ligases bladder cancer T-Lymphocyte Subsets Animal Disease Models deficiency Young Adult Follow-Up Studies Tandem Mass Spectrometry Muscle Neoplasms ras Proteins Paclitaxel Premenopause gemcitabine plus cisplatin Platelet-Derived Growth Factor Preclinical Drug Evaluation therapeutic adverse ErbB-2 Receptor Rectal Neoplasms Epidermal Growth Factor Receptor Adenocarcinoma Radiotherapy Nuclear factor kappaB NF-kB Amyloid beta-Protein Precursor Triple Negative Breast Neoplasms Urinary Bladder Neoplasms statistics & numerical data Cell Cycle Proteins effects Retrospective Studies Quinazolines Platelet-Derived Growth Factor beta Receptor
Last updated on Friday, July 10, 2020